XBB.1.5 is a sub-lineage of the SARS-CoV-2 lineage XBB, and is currently estimated to have a large growth advantage over previously circulating lineages in North America (139%) and Europe (137%), although these estimates are associated with significant uncertainty. There is a possibility that this variant could have an increasing effect on the number of COVID-19 cases in the EU/EEA, but not within the coming month as the variant is currently only present in the EU/EEA at very low levels.
Lesen Sie weiter auf: Update on SARS-CoV-2 variants: ECDC assessment of the XBB.1.5 sub-lineage
Quelle: European Centre for Disease Prevention and Control
Titelbild/Grafik by European Centre for Disease Prevention and Control
Kommentare und Fragen
Möchten Sie zu diesem Artikel ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!Aktuelles von European Centre for Disease Prevention and Control
- Weekly COVID-19 country overview
- Strengthening the sustainability of MediPIET
- Joint ECDC-WHO/Europe mpox (monkeypox) surveillance bulletin
- Mpox (formerly named monkeypox) situation update, as of 17 January 2023
- ECDC assesses risk to the EU/EEA associated with Omicron XBB1.5 sub-lineage
- Ebola outbreak in Uganda, as of 11 January 2023
- EASA/ECDC provide guidelines for aviation as part of European response to COVID-19 developments in China
- Update on SARS-CoV-2 variants: ECDC assessment of the XBB.1.5 sub-lineage
- Impact of surge in China COVID-19 cases on epidemiological situation in EU/EEA
- The Mediterranean and Black Sea Programme in Intervention Epidemiology Training joins the global Training Programs in Epidemiology and Public Health Interventions network
-
Literatur-Tipp*
Die Allergie-Bibel. Ursachen – Symptome – Behandlung: Mit zahlreichen Tabellen allergieauslösender Substanzen (211)
* = Affiliate Links / Bilder von der Amazon Product Advertising API / Aktualisiert am: 31.01.2023
